Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT submitted an FDA application for relacorilant to treat platinum-resistant ovarian cancer, based on promising Phase 2 and 3 trial data.

Patients receiving the drug with nab-paclitaxel experienced notable improvements in survival outcomes without added safety risks. With relacorilant already designated as an orphan drug and a decision date set for December 30, 2025, this milestone marks Corcept’s second active NDA submission.

Relacorilant modulates cortisol activity via glucocorticoid receptors and has shown strong clinical potential. Backed by robust financials, including a 128% stock return over the past year and a current ratio of 3.07, Corcept is well-positioned to target the estimated 20,000 U.S. patients needing new therapies for platinum-resistant disease annually. If approved, this drug could significantly enhance treatment options and expand the company’s oncology portfolio.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharma firm specializing in therapies that regulate cortisol, a key hormone in body function. Its lead product, Korlym, is FDA-approved for treating Cushing’s syndrome, a condition caused by excess cortisol.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.